Biogen (BIIB) Stock
Fundamentals
Latest news
About Biogen
At Biogen, our mission is clear: we are pioneers in neuroscience. Biogen discovers, develops, and delivers worldwide innovative therapies for people living with serious neurological and neurodegenerative diseases as well as related therapeutic adjacencies. Biogen has the leading portfolio of medicines to treat multiple sclerosis, has introduced the first approved treatment for spinal muscular atrophy, commercializes biosimilars of advanced biologics, and is focused on advancing research programs in multiple sclerosis and neuroimmunology, Alzheimer’s disease and dementia, neuromuscular disorders, movement disorders, ophthalmology, immunology, neurocognitive disorders, acute neurology, and pain.
Key Executives
| Name | Title | Year Born |
|---|---|---|
| Mr. Christopher A. Viehbacher | President, CEO & Director | 1961 |
| Ms. Robin C. Kramer | Executive VP & CFO | 1966 |
| Ms. Nicole Murphy | Executive VP and Head of Pharmaceutical Operations & Technology | 1973 |
| Dr. Priya Singhal M.D., M.P.H. | Executive VP & Head of Development | 1968 |
| Mr. Sean Godbout | VP, Chief Accounting Officer & Global Corporate Controller | 1974 |
| Mr. Guy Hadari | Chief Information Officer | — |
| Mr. Tim Power M.B.A., Ph.D. | Head of Investor Relations | — |
| Mr. Michael John Parini J.D. | Chief Legal Officer | 1974 |
| Ms. Natacha Gassenbach | Chief Communication Officer & Head of Corporate Affairs | — |
| Mr. Adam Keeney Ph.D. | Executive VP & Head of Corporate Development | 1977 |



